0
Summaries for Patients |

Influenza Vaccine to Protect Mothers and Their Babies FREE

[+] Article and Author Information

The full report is titled “Maternal Immune Response and Neonatal Seroprotection From Single Dose of a Monovalent Nonadjuvanted 2009 Influenza A(H1N1) Vaccine. A Single-Group Trial.” It is in the 6 December 2011 issue of Annals of Internal Medicine (volume 155, pages 733-741). The authors are V. Tsatsaris, C. Capitant, T. Schmitz, C. Chazallon, S. Bulifon, D. Riethmuller, O. Picone, P. Poulain, F. Lewin, F. Lainé, E. Jacqz-Aigrain, J.P. Aboulker, and O. Launay, for the Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group.


Ann Intern Med. 2011;155(11):I-52. doi:10.7326/0003-4819-155-11-201112060-00002
Text Size: A A A

What is the problem and what is known about it so far?

Pregnant women are advised to receive influenza vaccine (a flu shot) each year because influenza infection can be more severe when it occurs during pregnancy. Antibody (disease-fighting protein) that is produced in pregnant women after they receive influenza vaccine can not only protect them from influenza but can pass through the placenta to the fetus and protect their newborn babies from influenza as well. A new pandemic strain, influenza 2009 A(H1N1), appeared worldwide in 2009. Pregnant women were reported to be at especially high risk for complications and death from this new strain of influenza.

Why did the researchers do this particular study?

To see whether pregnant women who received a newly developed vaccine against influenza 2009 A(H1N1), called A(H1N1v), produced enough antibody to be protected against infection with influenza and whether the antibody would be passed through the placenta to the fetus in protective levels.

Who was studied?

Healthy pregnant women were enrolled in the study between weeks 22 and 32 of their pregnancies and followed until 3 months after delivery. They received a single injection of A(H1N1v) vaccine in the arm.

How was the study done?

Blood was periodically drawn from pregnant women after they received the vaccine, when they gave birth, and 3 months later. At delivery, blood was also drawn from the umbilical cord after it was cut. The blood was tested to determine the levels of antibody against influenza 2009 A(H1N1) in the mothers and in the cord blood. The level of antibody in cord blood reflected how much was present in the blood of the newborn baby.

What did the researchers find?

Antibody levels considered high enough to protect against infection with influenza 2009 A(H1N1) were found in the blood of almost all the mothers and babies. Although some serious adverse events occurred in mothers and babies after vaccination, an expert committee did not consider any to be related to the vaccine. No documented cases of influenza occurred in the mothers or babies.

What were the limitations of the study?

Only healthy women at 22 weeks of pregnancy or beyond were included in the study. Too few women were studied to determine whether the vaccine could have caused uncommon side effects.

What are the implications of the study?

After pregnant women receive a single dose of influenza A(H1N1v) vaccine, they and their newborn babies acquire levels of antibody that should protect them from being infected with influenza 2009 A(H1N1). The influenza vaccine being given for the 2011 to 2012 influenza season is directed against both influenza 2009 A(H1N1) and seasonal influenza; thus, women need to receive only 1 injection to protect against both types of influenza.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)